New drug combo shows promise for rare blood disorder
NCT ID NCT04328727
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding eltrombopag (a platelet booster) to standard immune-suppressing drugs (r-ATG and cyclosporine A) helps patients with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. Thirty-six East-Asian adults and children who had not yet been treated took part. The main goal was to see how many achieved normal blood counts by 26 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
eltrombopag (a drug that boosts platelet production), rabbit anti-thymocyte globulin (an immune-suppressing drug), and cyclosporine A (an immune-suppressing drug)
What this could lead to
If successful, this combination could help more patients with severe aplastic anemia achieve normal blood counts, reducing the need for transfusions and improving quality of life.
What could go wrong
This is a small, early-phase study (36 patients) with no control group, so results may not apply broadly. The drugs can cause serious side effects like infections or bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE APLASTIC ANEMIA (SAA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Guangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
Zhengzhou, Henan, 450052, China
-
Novartis Investigative Site
Nanchang, Jiangxi, 330006, China
-
Novartis Investigative Site
Changchun, Jilin, 130021, China
-
Novartis Investigative Site
Tianjin, 300020, China
-
Novartis Investigative Site
Tianjin, 300052, China
-
Novartis Investigative Site
Nagoya, Aichi-ken, 466 8560, Japan
-
Novartis Investigative Site
Fukuoka, Fukuoka, 812-8582, Japan
-
Novartis Investigative Site
Chuo Ku, Tokyo, 104 8560, Japan
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 06351, South Korea
-
Novartis Investigative Site
Kaohsiung City, 83301, Taiwan